The Incidence of Phlebitis in Patients Receiving Amiodarone Administration
Article Sidebar
Published:
Feb 20, 2017
Keywords:
phlebitis, amiodarone
Main Article Content
Abstract
OBJECTIVE: To determine the incidence of phlebitis after amiodarone administration in Bangkok Hospital Rayong, and to study the factors affecting phlebitis in patients receiving intravenous amiodarone.
MATERIALS AND METHODS: The retrospective study was conducted by reviewing patient medical records from all patients who received intravenous amiodarone during January 2011- December 2014. Concentration, type of dilute solution, duration of amiodarone therapy, peripheral intravenous size of catheter, age and underlying disease were examined. Descriptive statistics were used to analyze concentration, type of solution, duration, peripheral intravenous size of catheter, age and underlying disease. Chi - square test was used to analyze the factors affecting the phlebitis.
RESULTS: In the sample of 127 patients, 16 patients had phlebitis and the incidence of phlebitis was 12.6%. Phlebitis occurred in 14.4% of patients given a concentration ≤ 2 mg/ml and 6.7% concentration more than 2 mg/ml. Depending on the size of the catheter, it was found that 32.1% of phlebitis occurred in patients who received a catheter 22-gauge (G) size and larger whereas none of the patients who received a catheter 24-G size presented with phlebitis. Regarding the duration of amiodarone administration, 35% of patients received amiodarone administered >24-48 hours and 50% of these received medication in > 48 hours while in those who received medication in ≤ 24 hours, the occurrence of phlebitis was only 7.6%. The duration of amiodarone administration was significantly associated with phlebitis.
CONCLUSION:The incidence of phlebitis occurrence by amiodarone intravenous administration at peripheral entry mainly radial vein and few via cubital vein was studied, and we found that by using catheter 24-G, phlebitis will not occur, regardless of the concentration, duration and dilution (mixed with DW or NSS). The explanation for this is the faster speed of administration in catheter 24-G than the larger size of catheter resulting in the amiodarone not aggregating and combining with platelets, white blood cells and red blood cells that cause phlebitis.
MATERIALS AND METHODS: The retrospective study was conducted by reviewing patient medical records from all patients who received intravenous amiodarone during January 2011- December 2014. Concentration, type of dilute solution, duration of amiodarone therapy, peripheral intravenous size of catheter, age and underlying disease were examined. Descriptive statistics were used to analyze concentration, type of solution, duration, peripheral intravenous size of catheter, age and underlying disease. Chi - square test was used to analyze the factors affecting the phlebitis.
RESULTS: In the sample of 127 patients, 16 patients had phlebitis and the incidence of phlebitis was 12.6%. Phlebitis occurred in 14.4% of patients given a concentration ≤ 2 mg/ml and 6.7% concentration more than 2 mg/ml. Depending on the size of the catheter, it was found that 32.1% of phlebitis occurred in patients who received a catheter 22-gauge (G) size and larger whereas none of the patients who received a catheter 24-G size presented with phlebitis. Regarding the duration of amiodarone administration, 35% of patients received amiodarone administered >24-48 hours and 50% of these received medication in > 48 hours while in those who received medication in ≤ 24 hours, the occurrence of phlebitis was only 7.6%. The duration of amiodarone administration was significantly associated with phlebitis.
CONCLUSION:The incidence of phlebitis occurrence by amiodarone intravenous administration at peripheral entry mainly radial vein and few via cubital vein was studied, and we found that by using catheter 24-G, phlebitis will not occur, regardless of the concentration, duration and dilution (mixed with DW or NSS). The explanation for this is the faster speed of administration in catheter 24-G than the larger size of catheter resulting in the amiodarone not aggregating and combining with platelets, white blood cells and red blood cells that cause phlebitis.
Article Details
How to Cite
1.
Intarajareansuk U. The Incidence of Phlebitis in Patients Receiving Amiodarone Administration. BKK Med J [Internet]. 2017 Feb. 20 [cited 2024 Nov. 21];13(1):45. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/221789
Section
Original Article
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Norton L, Ottoboni LK, Varady A, et al. Phlebitis in amiodarone administration: incidence, contributing factors, and clinical implications. Am J Crit Care 2013;22(6):498-505.
2. Spiering M. Peripheral amiodarone related phlebitis: an institutional nursing guideline to reducepatient harm. J Infus Nurs 2014.37(6):453-460.
3. Slim AM,Roth JE, Duffy B, et al. The incidence of phlebitis with intravenous amiodarone at guideline dose recommendation. Mil Med 2007;172(12):1279-83.
4. Ratana J, Kaewnum P, Sealim S, et al. The mechanism affecting the incidence of phlebitis from the use of IV Amiodarone.2014. (Accessed February 15, 2015 at http://drug.pharmacy.psu.ac.th/Question.asp?ID=7758&gid=1)
5. Ravin W, Phipatanpanit P. Decreased incidence of phlebitis from Amiodarone and Vasopressor. 2008:1Quality Conference 15 Ramathibadi hospital.
6. Higginson R, Parry A. Phlebitis: treatment, care and prevention. Nurs Times 2011;107(36):18-21.
7. anchaivijit S. Infection in hospital (3rd edition). Bangkok:Journals and publications Section, Department of Medical Education Technology, Faculty of Medicine, Siriraj Hospital,Mahidol University; 2001.
8. Medical nursing section, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University.Phlebitis. 2011. (Accessed February 15, 2015 at http://www.med.cmu.ac.th/hospital/nintmed/2012/interestingarticle/85-phlebitis-article.html).
2. Spiering M. Peripheral amiodarone related phlebitis: an institutional nursing guideline to reducepatient harm. J Infus Nurs 2014.37(6):453-460.
3. Slim AM,Roth JE, Duffy B, et al. The incidence of phlebitis with intravenous amiodarone at guideline dose recommendation. Mil Med 2007;172(12):1279-83.
4. Ratana J, Kaewnum P, Sealim S, et al. The mechanism affecting the incidence of phlebitis from the use of IV Amiodarone.2014. (Accessed February 15, 2015 at http://drug.pharmacy.psu.ac.th/Question.asp?ID=7758&gid=1)
5. Ravin W, Phipatanpanit P. Decreased incidence of phlebitis from Amiodarone and Vasopressor. 2008:1Quality Conference 15 Ramathibadi hospital.
6. Higginson R, Parry A. Phlebitis: treatment, care and prevention. Nurs Times 2011;107(36):18-21.
7. anchaivijit S. Infection in hospital (3rd edition). Bangkok:Journals and publications Section, Department of Medical Education Technology, Faculty of Medicine, Siriraj Hospital,Mahidol University; 2001.
8. Medical nursing section, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University.Phlebitis. 2011. (Accessed February 15, 2015 at http://www.med.cmu.ac.th/hospital/nintmed/2012/interestingarticle/85-phlebitis-article.html).